Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Restructuring expenses by Quarter
Restructuring expenses — Research and development ($M) ($M)
Gilead Sciences Restructuring expenses: $14M in Q1 2026, down 63.2% from a year earlier.
Latest, Q1 2026
14
Period ended Mar 31, 2026
Change on a year earlier
-63.2%
38 in Q1 2025
History
9 quarters
Since Q1 2024
Sources
5
Documents cited below
Where the Q1 2026 figure comes from
Source: Form 10-Q (filed 2026-05-07) ↗
Reported in Form 10-Q / 10-K Restructuring Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring expenses — Research and development ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | 14 | -63.2% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 16 | -46.7% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 8 | +60.0% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 6 | -53.8% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 38 | -24.0% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 30 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 5 | – | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 13 | – | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 50 | – | Form 10-Q (filed 2025-05-07) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Restructuring expenses ($M), quarterly Q1 2024–Q1 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/restruct-exp-rd
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.